Liver Transplantation for the Treatment of Moderately or... : Annals of Surgery (original) (raw)

Feature

Liver Transplantation for the Treatment of Moderately or Well-Differentiated Hepatocellular Carcinoma

Cillo, Umberto MD*; Vitale, Alessandro MD*; Bassanello, Marco MD*; Boccagni, Patrizia MD*; Brolese, Alberto MD*; Zanus, Giacomo MD*; Burra, Patrizia MD†; Fagiuoli, Stefano MD†; Farinati, Fabio MD†; Rugge, Massimo MD, PhD, FACS‡; D'Amico, Davide Francesco MD, FACS*

From the *Clinica Chirurgica I, Dipartimento di Scienze Chirurgiche e Gastroenterlogiche, †Divisione di Gastroenterologia, Dipartimento di Scienze Chirurgiche e Gastroenterlogiche, ‡II Unità Operativa di Anatomia Patologica, University of Padua, Italy.

Reprints: Prof. Umberto Cillo, MD, Clinica Chirurgica 1°, Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine Via Giustiniani 2, Policlinico III piano, 35128 Padova, Italy. Email: [email protected].

Objective:

To determine the long-term results of liver transplantation for well- or moderately differentiated hepatocellular carcinoma (HCC).

Summary Background Data:

HCC patient selection for liver transplantation remains controversial, and deciding exclusively on the strength of criteria such as number and size of nodules appears prognostically inaccurate.

Methods:

Since 1991, preoperative tumor grading has been used at our center to establish whether a patient with HCC is fit for transplantation. Poorly differentiated HCC cases were excluded, while size and number of nodules were not considered as absolute selection criteria. Thirty-three patients with moderately or well-differentiated HCC were prospectively studied after liver transplantation. A group of 15 patients with incidental HCC transplanted during the same period were also evaluated and compared with the 33 patients with preoperatively diagnosed HCC.

Results:

On histologic examination, 38% of the entire group of 48 patients did not meet the “Milan criteria” and 42% were pTNM stages III and IV. The median follow-up was 44 months. The 5-year actuarial survival rate was 75% and recurrence-free survival was 92%. HCC recurred in only 3 patients (6%). The only histomorphologic variable differing significantly between incidental and nonincidental HCC was nodule size. The timing of diagnosis (incidental vs. nonincidental HCC), the Milan criteria, and the TNM stage revealed no statistically significant impact on overall and recurrence-free survival rates.

Conclusions:

The routine pre-orthotopic liver transplantation tumor grading may represent a valid tool in the selection of unresectable HCC patients for transplantation.